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The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell
lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal
mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus
a promising new targeted therapy for lymphoma.Aberrant patterning of epigenetic marks is
a fundamental hallmark of human cancer.
Studies exploring genome-wide distribu-
tion of DNA methylation and histone
modifications consistently reveal pro-
found perturbations in primary human
tumor specimens (Baylin and Jones,
2011). Such findings have contributed to
the increasing enthusiasm for ‘‘epigenetic
therapy’’ to reprogram the epigenome of
tumor cells. Two recent reports have
extended this paradigm to an exciting
new therapeutic target, EZH2.
EZH2 is the core enzymatic subunit of
an epigenetic gene-silencing complex
called polycomb repressive complex 2
(PRC2). EZH2 is a SET domain histone
methyltransferase that preferentially cata-
lyzes histone 3 lysine 27 (H3K27) methyla-
tion, a repressive mark that maintains
epigenetic silencing of genes (Chase and
Cross, 2011). EZH2 is active only when
associated with other PRC2 core compo-
nents EED, SUZ12, and RbAp48 (Chase
and Cross, 2011). During lymphopoiesis,
EZH2 is required for developing pre-B
cells to acquire a full spectrum of immu-
noglobulin VDJ recombinants (Su et al.,
2003). However, EZH2 expression rea-
ches its peak when mature B cells are
stimulated to form germinal centers
(GCs) and undergo immunoglobulin
affinity maturation (Velichutina et al.,
2010). GC B cells are uniquely adapted
to tolerate rapid proliferation and simulta-
neous genotoxic stress, which enables
them to generate high-affinity antibodies.
GC B cells give rise to the most common
types of B cell lymphomas including
diffuse large B cell lymphomas (DLBCLs)
and follicular lymphomas (FLs).
Remarkably, 20% of DLBCLs and 10%
of FLs display heterozygous somaticmutations of EZH2 involving Y641 or
A677 (Morin et al., 2010). Thesemutations
enable EZH2 tomore efficiently add a third
methyl group to H3K27 (Sneeringer et al.,
2010). EZH2 mutant DLBCL cells exhibit
increased abundance of H3K27me3 and
reduction of H3K27me1 (Morin et al.,
2010). The significance of this change is
unknown, but presumably would facilitate
more stable or potent repression of EZH2
target genes. Until now, it has been
unclear whether the relatively subtle
change in the stoichiometry of methylated
H3K27 in EZH2 mutant DLBCLs would
exert significant influence on the malig-
nant phenotype. Regardless of the muta-
tion status, a majority of DLBCLs feature
high expression of EZH2, likely reflecting
their GC origin (Velichutina et al., 2010).
Moreover, genomics studies in primary
human GC B cells showed that EZH2
represses numerous proliferation check-
point genes, suggesting a role in facili-
tating proliferation (Velichutina et al.,
2010). Hence, it is of great interest to
address whether mutations in EZH2
contribute significantly to maintain the
survival of lymphoma cells or just repre-
sent subtle ‘‘tuning’’ of an epigenetic
silencing mechanism that is already
present.
Some of these questions can now be
addressed thanks to the development of
highly selective EZH2 inhibitors, an
achievement with important scientific
and clinical implications. Using high-
throughput screening for inhibitors of the
PRC2 complex followed by medicinal
chemistry optimization, two research
groups generated low nanomolar potency
small molecule EZH2 inhibitors (Knutson
et al., 2012; McCabe et al., 2012). These
small molecules displayed remarkableCancer Cell 22, Nselectivity for EZH2 and showed similar
efficacy against wild-type and mutant
forms of EZH2. Notably, when applied to
a large panel of B cell lymphoma cell lines,
EZH2 inhibitors were most effective
against DLBCLs, especially those with
EZH2 point mutations. The compound
induced apoptotic cell death in addition
to proliferation arrest in the most sensitive
cell lines. EZH2 mutant DLBCL cells are
therefore exquisitely dependent on EZH2
to maintain their growth and survival.
Nononcogene addiction to EZH2 may
also occur in at least a subset of EZH2
wild-type DLBCLs, perhaps reflecting
a potential biological role for EZH2 in
normal GC B cells.
In an attempt to link the biologic actions
of EZH2 inhibitor to gene expression and
H3k27 methylation, a series of profiling
experiments were performed (McCabe
et al., 2012). The most EZH2-dependent
cell lines showed predominant gene upre-
gulation after exposure to GSK126, one
of the EZH2 inhibitors, associated with
a heavier pretreatment burden of
H3K27me3 (McCabe et al., 2012). Tran-
scriptional response was stronger in
EZH2 mutant versus wild-type cell lines.
However, the logic of these associations
seems to break down when comparing
differentially regulated genes among the
most GSK126-responsive cell lines. It
would not be unreasonable to expect
EZH2 mutant cell lines to display a strong
signature of GSK126-induced genes
given their shared biological dependence
on EZH2. Yet, only 35 genes overlapped
in four out of the five cell lines profiled.
Independent of experimental questions,
such as whether heterogeneity is a
product of cell line epigenetic diversifica-
tion in vitro or whether gene expressionovember 13, 2012 ª2012 Elsevier Inc. 569
Figure 1. EZH2 Inhibitors Target Mutant and Wild-type EZH2 in DLBCL Cells with Equal
Potency
EZH2may form an active PRC2 complex in both nucleus and cytoplasm, although its cytoplasmic function
in B cells is unknown. Mutant EZH2 mediates both survival and proliferation, whereas wild-type might be
mostly linked to proliferation. Mutant EZH2 more strongly represses chromatin (red) than wild-type EZH2
(yellow) by inducing greater levels of H3K27me3. Wild-type EZH2 represses proliferation-associated
genes such as CDKN1A and CDKN1B, whereas the target genes of mutant EZH2 may be different or
more variable. Mutant EZH2, and perhaps wild-type EZH2 to a lesser extent, may contribute to epigenetic
instability such as more heterogeneous distribution of H3K27me3. Newly-described EZH2 inhibitors
(EZH-i) epigenetically reprogram DLBCL cells with mutant or wild-type EZH2 (green), leading to the
derepression of target genes and perhaps alleviation of epigenetic instability manifested as proliferation
arrest and cell death.
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Previewsmicroarrays have the necessary dynamic
range to robustly capture changes in low
abundance transcripts, it is interesting
to consider the implications of these
results. For example, might it be possible
that EZH2 mutation enables a state of
‘‘epigenetic instability’’ whereby H3K27
patterning evolves stochastically such
that tumors in individual patients may
silence different sets of genes, any combi-
nation of which might have similar effects
in facilitating transformation? There is
a precedent for such a notion in that prolif-
erating GC B cells display a greater
degree of cytosine methylation heteroge-
neity than resting B cells (Shaknovich
et al., 2011). Likewise, it is conceivable
that proliferation in GC B cells could also
drive H3K27 methylation heterogeneity.
Alternatively, it is possible that only a small
number of genes contribute in a meaning-
ful way to the oncogenic effects of mutant
EZH2, in which case, the nonoverlapping
genes may represent mostly noise. It is
also intriguing to consider whether gene570 Cancer Cell 22, November 13, 2012 ª20expression and/or H3K27 methylation
changes might be a red herring. For
example, PRC2 complex is also localized
to cytoplasm, and in T cells, may regulate
processes such as actin polymerization
(Su et al., 2005). Might the effect of
EZH2 inhibitors be related to nonepige-
netic mechanisms? These provocative
results challenge the field to perform func-
tional assays and modeling to resolve
these questions (Figure 1).
Regardless of these deeper mecha-
nistic questions, the report by McCabe
et al. (2012) has major translational impli-
cations. Even though EZH2 is an essential
protein during development, mice toler-
ated the drug without apparent toxicity.
Most importantly, GSK126 displayed an
extremely powerful anti-lymphoma effect
on human DLBCL cell line xenografts,
with complete growth inhibition at lower
doses and tumor eradication at higher
doses of drug (McCabe et al., 2012).
Tumor eradication is not easily achievable
in DLBCL xenograft studies, raising the12 Elsevier Inc.possibility that mutant EZH2 might
play a role in self-renewal of putative
lymphoma propagating cells. EZH2 is
known to play a key role in the self-
renewal of stem cells (Chase and Cross,
2011), so it is conceivable that, in addition
to growth arrest and apoptosis, EZH2
inhibitors might promote the extinction
of EZH2-dependent lymphomagenic
clones. These data provide a compelling
case for testing EZH2 inhibitors in clinical
trials for patients with DLBCL harboring
mutant EZH2 and/or high H3K27methyla-
tion levels. Finally, in addition to DLBCL,
EZH2 is also mutated in FL and is overex-
pressed in solid tumors including prostate
and breast cancer (Chase and Cross,
2011). Therefore, the rational translation
of EZH2 inhibitor therapy holds great
promise toward improved efficacy and
reduced toxicity for patients with these
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